Neopharma Expands Into Biotechnology and Nanotechnology-Based Research and Development
Neopharma has ventured into biotechnology and nanotechnology-based research and manufacturing capabilities. The announcement preceded a ground breaking ceremony held under the patronage and in the presence of His Highness Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister for Higher education and Scientific Research, and Chairman of Neopharma.
His Excellency Abdullah Humaid Al Mazroei, Vice-Chairman, and Dr. B R Shetty, Managing Director and CEO, Neopharma, said the AED250 million facilities will manufacture nutraceuticals, injectable preparations, topical applications, ophthalmic products and aerosols. Manufacturing lines are concurrently being set up for a group of antibiotic drugs called 'cephalosporins', with separate areas allocated for both oral and injectable variations.
Dr.B. R. Shettysaid: "Neopharma is aggressively pressing ahead with its organic growth initiatives. The immense support of Bank of Baroda, the lead financing partner, is a significant stimulus that complements our efforts.
"The new facilities will mark our foray into high-technology based research and development (R&D). In the long-term, our initiatives will contribute to creating suitable opportunities for students in the country and help create a professional talent pool."
Neopharma's facilities that are expected to begin operations within 14 months will be designed on the guidelines recommended by US FDA.
Other news from the department manufacturing
Most read news
More news from our other portals
Last viewed contents
MBL scientists find genes linked to human neurological disorders in sea lamprey genome - Discovery will accelerate research on Alzheimer's disease, Parkinson's disease and spinal cord injury
Merck Proposes the Creation of a Global Alliance for the Elimination of Schistosomiasis
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
